The Basics
What is Indium In 111 Pentetreotide?
Ued for radioimaging neuroendocrine tumor cells.
Brand names for Indium In 111 Pentetreotide
Na
How Indium In 111 Pentetreotide is classified
Radiopharmaceuticals, Indium Radioisotopes, Diagnostic Agents
Indium In 111 Pentetreotide During Pregnancy
Indium In 111 Pentetreotide pregnancy category
Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Indium In 111 Pentetreotide while pregnant
N/A
Taking Indium In 111 Pentetreotide While Breastfeeding
What are recommendations for lactation if you're taking Indium In 111 Pentetreotide?
Information in this record refers to the use of indium In 111 pentetreotide as a diagnostic agent. Recommendations for use in breastfeeding mothers range from no withholding of breastfeeding necessary[1] to 60 hours after a dose of 100 to 220 MBq.[2][3] In some cases, imaging with indium In 111 pentetreotide is followed shortly by a therapy (peptide receptor radiotherapy; PRRT) that uses yttrium 90 or lutetium 177 compounds to selectively irradiate tumors. These agents may pose additional radiation risk to the nursing infant.[4] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]
Maternal / infant drug levels
Information in this record refers to the use of indium In 111 pentetreotide as a diagnostic agent. Recommendations for use in breastfeeding mothers range from no withholding of breastfeeding necessary[1] to 60 hours after a dose of 100 to 220 MBq.[2][3] In some cases, imaging with indium In 111 pentetreotide is followed shortly by a therapy (peptide receptor radiotherapy; PRRT) that uses yttrium 90 or lutetium 177 compounds to selectively irradiate tumors. These agents may pose additional radiation risk to the nursing infant.[4] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]
Possible effects of Indium In 111 Pentetreotide on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Indium In 111 Pentetreotide
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Balon HR, Brown TL, Goldsmith SJ et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317-24. PMID: 22068564
2. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation
3. National Radiation Protection Board (UK). Administration of radioactive substances advisory committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2019. https://assets.publishing.service.gov.uk/government/…/file/…/ARSAC_NfG_2019.pdf
4. Balon HR, Brown TL, Goldsmith SJ et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317-24. PMID: 22068564
5. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203
6. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/
7. Mallinckrodt Inc. OctreoScan product information. 2006;October 25.
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
